 |
|
Acyclovir-Resistant Genital Herpes Among Persons Attending Sexually Transmitted Disease and Human Immunodeficiency Virus Clinics
Michele Reyes, PhD;
Nazerah S. Shaik, MPH;
Judith M. Graber, MS;
Rosane Nisenbaum, PhD;
Neal T. Wetherall, PhD;
Keiji Fukuda, MD;
William C. Reeves, MD;
for the Task Force on Herpes Simplex Virus Resistance
Arch Intern Med. 2003;163:76-80.
Background Genital herpes is epidemic in the United States; long-term acyclovir therapy is common; and long-term use of antimicrobials in suppressive doses favors development of resistance.
Objective To determine the prevalence of and risk factors for acyclovir-resistant genital herpes.
Methods We identified and attempted to enroll all patients 18 years or older with suspected genital herpes who attended 22 sexually transmitted disease and human immunodeficiency virus (HIV) clinics in the United States between October 1996 and April 1998. We conducted standardized interviews of all consenting patients. Lesions were cultured, and isolates were typed as herpes simplex virus (HSV) 1 or HSV-2 and tested for acyclovir sensitivity (using a 50% inhibitory concentration of 2 µg/mL) by plaque reduction, which was independently confirmed.
Results Herpes simplex virus was isolated from 2088 of 3602 patients, and 90.2% of isolates were HSV-2. Fifteen isolates, all HSV-2, were acyclovir resistant. Three (0.18%) of 1644 HIV-negative patients had acyclovir-resistant isolates (95% confidence interval [CI], 0.04%-0.5%); resistance was associated with oral (P<.006) and topical (P<.001) acyclovir use. Twelve (5.3%) of 226 HIV-positive patients yielded resistant HSV isolates (95% CI, 2.8%-9.1%); resistance was associated with oral acyclovir use (P<.001), duration of the current episode (P<.001), history of recurrent genital herpes (P<.01), and low CD4 cell count (P<.05).
Conclusions In the 15 years following licensure of acyclovir, resistance to the drug remains low among immunocompetent patients. However, 5% of HIV-positive patients had resistant HSV-2 isolates. Continued surveillance is essential to monitor changes in acyclovir resistance and to characterize the clinical and public health importance of acyclovir-resistant HSV.
From the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga (Drs Reyes, Shaik, Graber, Nisenbaum, Fukuda, and Reeves); ViroMed Laboratories Inc, Minneapolis, Minn (Dr Wetherall). Dr Wetherall is employed by ViroMed Laboratories, Minneapolis, Minn, which has had contractual arrangements with Glaxo Wellcome unrelated to this study. Dr Davis was an employee of Glaxo Wellcome at the time of this study, and Drs Kern, Corey, Crumpacker, Darby, and Sacks have served as paid consultants to Glaxo Wellcome.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Resistant Herpes Simplex Virus Infection and HIV: A Potential Diagnostic and Therapeutic Dilemma
Bush et al.
Lab Med 2011;42:452-457.
ABSTRACT
| FULL TEXT
Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management
Piret and Boivin
Antimicrob. Agents Chemother. 2011;55:459-472.
ABSTRACT
| FULL TEXT
European guideline for the management of genital herpes, 2010
Patel et al.
Int J STD AIDS 2011;22:1-10.
ABSTRACT
| FULL TEXT
Use of Acyclovir for Suppression of Human Immunodeficiency Virus Infection Is Not Associated with Genotypic Evidence of Herpes Simplex Virus Type 2 Resistance to Acyclovir: Analysis of Specimens from Three Phase III Trials
Watson-Jones et al.
J. Clin. Microbiol. 2010;48:3496-3503.
ABSTRACT
| FULL TEXT
Impaired Sleep in Chronic Fatigue Syndrome: How Is It Best Measured?
Creti et al.
J Health Psychol 2010;15:596-607.
ABSTRACT
Role of Nectin-1, HVEM, and PILR-{alpha} in HSV-2 Entry into Human Retinal Pigment Epithelial Cells
Shukla et al.
IOVS 2009;50:2878-2887.
ABSTRACT
| FULL TEXT
9.12 Sexually transmitted infections
Kamb and Douglas
Oxford Textbook of Public Health 2009;5:med-9780199218707-chapter-med-9780199218707-chapter.
ABSTRACT
| FULL TEXT
Herpes Simplex Virus (HSV) Suppression with Valacyclovir Reduces Rectal and Blood Plasma HIV-1 Levels in HIV-1/HSV-2-Seropositive Men: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Zuckerman et al.
The Journal of Infectious Disease 2007;196:1500-1508.
ABSTRACT
| FULL TEXT
Management of Herpes Simplex Virus Type 2 Infection in HIV Type 1-Infected Persons
Strick et al.
Clinical Infectious Diseases 2006;43:347-356.
ABSTRACT
| FULL TEXT
Acyclovir Sensitivity of Sequential Herpes Simplex Virus Type 2 Isolates from the Genital Mucosa of Immunocompetent Women
Gupta et al.
The Journal of Infectious Disease 2005;192:1102-1107.
ABSTRACT
| FULL TEXT
Development of Herpes Simplex Virus Disease in Patients Who Are Receiving Cidofovir
Wyles et al.
Clinical Infectious Diseases 2005;41:676-680.
ABSTRACT
| FULL TEXT
Recent Developments in the Management of Herpes Simplex Virus Infection in HIV-Infected Persons
Bartlett
Clinical Infectious Diseases 2004;39:S237-S239.
FULL TEXT
Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients
Levin et al.
Clinical Infectious Diseases 2004;39:S248-S257.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Valacyclovir for the Suppression and Episodic Treatment of Herpes Simplex Virus in Patients with HIV
Warren et al.
Clinical Infectious Diseases 2004;39:S258-S266.
ABSTRACT
| FULL TEXT
Epidemiology of recurrent genital herpes simplex virus types 1 and 2
Solomon et al.
Sex. Transm. Infect. 2003;79:456-459.
ABSTRACT
| FULL TEXT
Valacyclovir for the Suppression of Recurrent Genital Herpes in Human Immunodeficiency Virus-Infected Subjects
DeJesus et al.
The Journal of Infectious Disease 2003;188:1009-1016.
ABSTRACT
| FULL TEXT
How Does Herpes Simplex Virus Type 2 Influence Human Immunodeficiency Virus Infection and Pathogenesis?
Wald and Corey
The Journal of Infectious Disease 2003;187:1509-1512.
FULL TEXT
Acyclovir Resistance Still Rare in Genital Herpes
JWatch Infect. Diseases 2003;2003:12-12.
FULL TEXT
|
